Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
589.25 USD | +0.19% | -0.44% | +61.07% |
12-06 | Berenberg: Novo Nordisk Faces Challenging Momentum Picture as Rivals Bite into Obesity Market | MT |
12-05 | Sector Update: Health Care Stocks Ease Late Afternoon | MT |
Sales 2023 * | 33.6B 2,673B | Sales 2024 * | 38.84B 3,090B | Capitalization | 530B 42,158B |
---|---|---|---|---|---|
Net income 2023 * | 5.29B 421B | Net income 2024 * | 10.69B 850B | EV / Sales 2023 * | 16,2x |
Net Debt 2023 * | 14.19B 1,129B | Net Debt 2024 * | 11.73B 933B | EV / Sales 2024 * | 13,9x |
P/E ratio 2023 * | 98,9x | P/E ratio 2024 * | 48,3x | Employees | 39,000 |
Yield 2023 * | 0,74% | Yield 2024 * | 0,87% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | +0.19% | ||
1 week | -0.44% | ||
Current month | -0.30% | ||
1 month | -1.00% | ||
3 months | +5.23% | ||
6 months | +32.99% | ||
Current year | +61.07% |
1 week
574.33
601.97

1 month
574.33
625.87

Current year
302.14
629.97

1 year
302.14
629.97

3 years
146.91
629.97

5 years
101.36
629.97

10 years
48.88
629.97

Managers | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 55 | 1995 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 50 | 2013 |
Alonzo Weems
CMP | Compliance Officer | - | 1996 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 62 | 2021 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 2009 |
Jon Fyrwald
BRD | Director/Board Member | 64 | 2004 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
26.31% | 475 M€ | -4.32% | - | |
14.50% | 4 M€ | +17.27% | - | |
10.26% | 16 M€ | 0.00% | - | |
10.20% | 212 M€ | +7.52% | ||
8.98% | 2,705 M€ | -2.75% |
Date | Price | Change | Volume |
---|---|---|---|
06/12/23 | 589.25 | +0.19% | 2,093,105 |
05/12/23 | 588.15 | +0.42% | 2,157,343 |
04/12/23 | 585.68 | +0.28% | 2,577,122 |
01/12/23 | 584.04 | -1.18% | 3,638,565 |
30/11/23 | 591.04 | -0.14% | 5,658,350 |
Delayed Quote Nyse, December 06, 2023 at 09:00 pm
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (46.6%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (20.3%);
- immunology diseases (11.8%);
- neurology (6.7%): primarily drugs used in treating depression and schizophrenia;
- other (14.6%).
Net sales are distributed geographically as follows: the United States (59.4%), Europe (16.9%), Japan (8.3%), China (5.9%) and other (9.5%).
Sector
Pharmaceuticals
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
589.25USD
Average target price
619.14USD
Spread / Average Target
+5.07%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.07% | 530 B $ | |
+44.35% | 438 B $ | |
-11.34% | 377 B $ | |
-4.79% | 268 B $ | |
-9.42% | 258 B $ | |
+0.98% | 200 B $ | |
-9.65% | 198 B $ | |
-43.81% | 163 B $ | |
+2.55% | 144 B $ | |
-4.20% | 117 B $ |

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition